Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.
SIV vaccine protection of rhesus macaques.
Symp Nonhum Primate Models AIDS. 1990 Nov 28-30;8:49 (abstract no. 33). Unique Identifier : AIDSLINE PRIM8/900033 Carlson JR; McGraw TP; Keddie E; Yee JL; Rosenthal A; Langlois AJ; Dickover R; Donovan R; Luciw PA; Jennings MB; et al; Departments of Pathology and Internal Medicine, School of; Medicine, California Primate Research Center, University of; California, Davis
Abstract:
Rhesus macaques (M.mulatta) immunized with an inactivated whole SIVmac vaccine and muramyl dipeptide (MDP) incomplete Freund's adjuvant (IFA) or aqueous suspension were challenged intravenously with 10 animal infectious doses (ID) (0.1 TCID/50) of cell free SIVmac. Whereas virus was readily recovered from the PBLs of 10 of 10 non-vaccinated controls following this challenge dose, virus was not recovered from the three animals that received the vaccine with MDP nor from one of two animals that received the vaccine with IFA and one of three animals that received the aqueous vaccine. The animals that were protected against challenge were those that had more detectable SIV antibody response to the envelope, both the outer glycoprotein (gp120) and the truncated transmembrane glycoprotein (gp31). Protected monkeys tended to have higher titers of syncytial inhibition antibody prior to challenge. An anamnestic response after challenge was observed only in the vaccinated monkeys that became infected. Vaccinated animals that became challenge-infected tended to live longer than infected controls. These results confirm those at other primate centers and indicate that killed whole SIV vaccines can protect against low challenge doses of SIV and prevent early death in those monkeys that do become infected. The mechanism of this protection remains undetermined. Initial results from a cross-challenge experiment done in collaboration with Dr. Murphey-Corb (Delta Regional Primate Research Center) indicate that SIVmac immunized monkeys are protected against IV challenge with 10 ID of SIVsm and, conversely, SIVsm immunized monkeys are protected against IV challenge with 10 ID of SIVmac. These two SIV strains differ by about 17% in envelope sequences indicating that the vaccine induced protection appears to be fairly broad. These findings add optimism to the possibility of an eventual AIDS vaccine.
Keywords: Acetylmuramyl-Alanyl-Isoglutamine/*IMMUNOLOGY Animal Antibodies, Viral/BIOSYNTHESIS Cells, Cultured Dose-Response Relationship, Immunologic *Freund's Adjuvant Leukocytes, Mononuclear/MICROBIOLOGY Macaca mulatta Simian Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL SIV/GROWTH & DEVELOPMENT/*IMMUNOLOGY Viral Envelope Proteins/IMMUNOLOGY *Viral Vaccines Virus Activation/IMMUNOLOGY ABSTRACT 910730
M9170961
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.
